CorMedix Inc. (CRMD) · Nov 2, 2026 · Other events
No new info
CorMedix’s earnings update contains no financial results or changed guidance, leaving the post-TDAPA story untouched until the November 12 call.
CorMedix is commercializing DefenCath while navigating its post-TDAPA reimbursement transition and integrating the acquired Melinta portfolio. Its prior outlook called for lower DefenCath pricing in the second half of 2026, with a potentially higher 2027 add-on payment as the key reimbursement variable.
This filing does not change that business story. It says only that CorMedix provided a business update ahead of a conference call expected on November 12, 2026, when it will discuss complete quarterly financial performance.
The 2027 reimbursement language is framing and risk disclosure, not new guidance. The filing references estimates and assumptions around the post-TDAPA Add-On, but supplies no revenue, pricing, utilization, margin, cash, or revised outlook figures. 〔0〕
Bottom line: This is a carrier for the November 12 earnings event, not an operating update. The DefenCath reimbursement transition remains the central issue, but this filing adds no new evidence on how execution is tracking it.
Complete quarterly results and conference call, November 12
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!